Bacterial Species Targeted by These Bacteriophages
The bacteriophages LH01 (Myoviridae), LL5 (Siphoviridae), T4D (Myoviridae), and LL12 (Myoviridae) specifically target and reduce Escherichia coli populations. 1
Evidence Basis
The PHAGE study directly evaluated this specific combination of four bacteriophages in human subjects. The study administered these exact phage strains—LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae—as a therapeutic cocktail to healthy adults with gastrointestinal distress 1.
Key Points About These Phages:
- Primary target: E. coli species in the gastrointestinal tract
- Safety profile: Demonstrated to be both safe and tolerable in human consumption at therapeutic doses 1
- Clinical effects: Participants showed improvements in gastrointestinal symptoms, with the treatment causing a significant decrease in aspartate aminotransferase levels (though remaining within clinically acceptable ranges) 1
Clinical Context
These phages were specifically formulated as a cocktail to selectively eliminate detrimental E. coli strains while potentially enhancing beneficial microbe populations in the gut 1. The T4 bacteriophage (T4D in this cocktail) is particularly well-characterized as an anti-E. coli phage, with antibodies against T4 existing in the majority of the healthy population 2.
Important caveat: While these phages target E. coli, their efficacy depends on strain-specific susceptibility testing, as phage activity can vary significantly between different bacterial isolates even within the same species 2, 3.